Cortical grey matter sodium accumulation is associated with disability and secondary progressive disease course in relapse-onset multiple sclerosis

Objective Sodium (23Na)-MRI is an emerging imaging technique to investigate in vivo changes in tissue viability, reflecting neuroaxonal integrity and metabolism. Using an optimised 23Na-MRI protocol with smaller voxel sizes and improved tissue contrast, we wanted to investigate whether brain total sodium concentration (TSC) is a biomarker for long-term disease outcomes in a cohort of patients with relapse-onset multiple sclerosis (MS), followed from disease onset. Methods We performed a cross-sectional study in 96 patients followed up ~ 15 years after a clinically isolated syndrome (CIS) and 34 healthy controls. Disease course was classified as CIS, relapsing-remitting MS or secondary progressive MS (SPMS). We acquired 1H-MRI and 23Na-MRI and calculated the TSC in cortical grey matter (CGM), deep grey matter, normal-appearing white matter (WM) and WM lesions. Multivariable linear regression was used to identify independent associations of tissue-specific TSC with physical disability and cognition, with adjustment for tissue volumes. Results TSC in all tissues was higher in patients with MS compared with healthy controls and patients who remained CIS, with differences driven by patients with SPMS. Higher CGM TSC was independently associated with Expanded Disability Status Scale (R2=0.26), timed 25-foot walk test (R2=0.23), 9-hole peg test (R2=0.23), Paced Auditory Serial Addition Test (R2=0.29), Symbol Digit Modalities Test (R2=0.31) and executive function (R2=0.36) test scores, independent of grey matter atrophy. Conclusions Sodium accumulation in CGM reflects underlying neuroaxonal metabolic abnormalities relevant to disease course heterogeneity and disability in relapse-onset MS. TSC and should be considered as an outcome measure in future neuroprotection trials.

[1]  Bertrand Audoin,et al.  Distribution of brain sodium accumulation correlates with disability in multiple sclerosis: a cross-sectional 23Na MR imaging study. , 2012, Radiology.

[2]  S. Reingold,et al.  Defining the clinical course of multiple sclerosis , 1996, Neurology.

[3]  David H. Miller,et al.  Gray matter atrophy is related to long‐term disability in multiple sclerosis , 2008, Annals of neurology.

[4]  Hillary C. M. Nelson The National Adult Reading Test , 1982 .

[5]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[6]  Hans Lassmann,et al.  Progressive multiple sclerosis: pathology and pathogenesis , 2012, Nature Reviews Neurology.

[7]  N. Larocca,et al.  The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. , 1989, Archives of neurology.

[8]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[9]  Sebastien Ourselin,et al.  Automatic sodium maps reconstruction using PatchMatch algorithm for phantom detection , 2016 .

[10]  L. Schad,et al.  Increased total sodium concentration in gray matter better explains cognition than atrophy in MS , 2017, Neurology.

[11]  D. Wade,et al.  The Adult Memory and Information Processing Battery (AMIPB) test of information-processing speed: a study of its reliability and feasibility in patients with multiple sclerosis , 2003, Clinical rehabilitation.

[12]  Tim Shallice,et al.  The Hayling and Brixton Tests , 1997 .

[13]  D. Bechtold,et al.  Axonal protection using flecainide in experimental autoimmune encephalomyelitis , 2004, Annals of neurology.

[14]  Xavier Golay,et al.  Sodium accumulation is associated with disability and a progressive course in multiple sclerosis. , 2013, Brain : a journal of neurology.

[15]  Sébastien Ourselin,et al.  Scale Factor Point Spread Function Matching: Beyond Aliasing in Image Resampling , 2015, MICCAI.

[16]  A. Thompson,et al.  Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis , 2002, Multiple sclerosis.

[17]  C. Poser,et al.  Diagnostic criteria for multiple sclerosis , 2001, Clinical Neurology and Neurosurgery.

[18]  Frederik Barkhof,et al.  Grey matter pathology in multiple sclerosis , 2008, The Lancet Neurology.

[19]  Lazar Fleysher,et al.  Sodium MRI of multiple sclerosis , 2016, NMR in biomedicine.

[20]  Lublin Fd,et al.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. , 1996 .

[21]  Lazar Fleysher,et al.  Brain intra- and extracellular sodium concentration in multiple sclerosis: a 7 T MRI study. , 2016, Brain : a journal of neurology.

[22]  Jia Newcombe,et al.  Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Sébastien Ourselin,et al.  A multi-time-point modality-agnostic patch-based method for lesion filling in multiple sclerosis , 2016, NeuroImage.

[24]  B Stoeckel,et al.  Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla. , 2010, Brain : a journal of neurology.

[25]  O Ciccarelli,et al.  Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome , 2017, Multiple sclerosis.

[26]  E. D’Angelo,et al.  Challenges and Perspectives of Quantitative Functional Sodium Imaging (fNaI) , 2018, bioRxiv.

[27]  M. Calabrese,et al.  Cortical lesion load associates with progression of disability in multiple sclerosis. , 2012, Brain : a journal of neurology.

[28]  Roberto Mutani,et al.  Grey Matter Pathology in Multiple Sclerosis , 2005, Journal of neuropathology and experimental neurology.

[29]  R. Rudick,et al.  Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients , 2006, Annals of neurology.

[30]  Stephen M. Rao,et al.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure. , 1999, Brain : a journal of neurology.

[31]  Bertrand Audoin,et al.  Topography of brain sodium accumulation in progressive multiple sclerosis , 2014, Magnetic Resonance Materials in Physics, Biology and Medicine.

[33]  David H. Miller,et al.  Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial , 2016, The Lancet Neurology.

[34]  Daniel Rueckert,et al.  Geodesic Information Flows: Spatially-Variant Graphs and Their Application to Segmentation and Fusion , 2015, IEEE Transactions on Medical Imaging.

[35]  X. Golay,et al.  Sodium (23Na) ultra-short echo time imaging in the human brain using a 3D-Cones trajectory , 2013, Magnetic Resonance Materials in Physics, Biology and Medicine.

[36]  A. Thompson,et al.  Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis , 2009, Multiple sclerosis.